A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: The MM-021 trial

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Hou, Jian ^a   Du, Xin ^b   Jin, Jie ^c   Cai, Zhen ^c   Chen, Fangping ^d   Zhou, Dao Bin ^e   Yu, Li ^f   Ke, Xiaoyan ^g   Li, Xiao ^h   Wu, Depei ⁱ   Meng, Fanyi ^j   Ai, Huisheng ^k   Zhang, Jingshan ^l   Wortman Vayn, Honeylet ^l   Chen, Nianhang ^l   Mei, Jay ^l   Wang, Jianmin ^m  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^f CHINESE PLA GENERAL HOSPITAL   (China)

^g PEKING UNIVERSITY THIRD HOSPITAL   (China)

^h Shanghai 6th Hospital   (China)

ⁱ THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^j SOUTHERN MEDICAL UNIVERSITY   (China)

^k The 307 PLA Hospital   (China)

^l CELGENE CORPORATION   (United States)

^m SECOND MILITARY MEDICAL UNIVERSITY   (China)

more..

Author keywords

Chinese Patients; Lenalidomide; Low dose Dexamethasone; Relapsed Refractory Multiple Myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ACUTE PANCREATITIS; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CONFUSION; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; KIDNEY FUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOOD CHANGE; MULTICENTER STUDY; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RASH; RELAPSE; RELAPSED OR REFRACTORY MULTIPLE MYELOMA; SIDE EFFECT; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; CHINA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; DEXAMETHASONE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84879047179     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-41     Document Type: Article

References (32)

1. Chen N, Lau H, Kong L, Chinese tumor annual registry of 2004 (edited by the National office of cancer prevention and treatment, National center for cancer registry, Bureau of disease control and prevention of the ministry of health) Chinese Union Medical College 2004 60
2. Analysis of the trend of incidence of malignant tumors in Shanghai region (from years 1972-1999). Liu E, Xiang Y, Jin F, Zhou S, Sun L, Fang R, Yuan Z, Gao L, Gao Y, Tumor 2004 24 11 15
3. The treatment of multiple myeloma: current status and progress. Qiu L, Chin J Pract Intern Med 2006 26 886 888
4. Improved survival in multiple myeloma and the impact of novel therapies. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA, Blood 2008 111 2516 2520 10.1182/blood-2007-10-116129 17975015
5. China treatment guideline for multiple myeloma. Chinese Multiple Myeloma Working Group, Chin J Intern Med 2008 47 869 872
6. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple Myeloma (010) Study Investigators, N Engl J Med 2007 357 2123 2132 10.1056/NEJMoa070594 18032762 (Pubitemid 350146107)
7. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma (009) Study Investigators, N Engl J Med 2007 357 2133 2142 10.1056/NEJMoa070596 18032763 (Pubitemid 350146108)
8. Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. Iida S, Chou T, Okamoto S, Nagai H, Hatake K, Murakami H, Takagi T, Shimizu K, Lau H, Takeshita K, Takatoku M, Hotta T, Int J Hematol 2010 92 118 126 10.1007/s12185-010-0624-7 20559759
9. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC, Blood 2002 100 3063 3067 10.1182/blood-2002-03-0996 12384400 (Pubitemid 35217050)
10. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, Eastern Cooperative Oncology Group, Lancet Oncol 2010 11 29 37 10.1016/S1470-2045(09)70284-0 19853510
11. Revlimid (lenalidomide) prescribing information Summit, NJ, USA: Celgene Corporation 2009 http://www.revlimid.com/docs/Revlimid-Full-PI.pdf Accessed 24 May 2013
12. Revlimid. Summary of product characteristics 2012 http://www.medicines. org.uk/emc/medicine/19841/SPC/Revlimid/ Accessed 24 May 2013
13. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E, Eur J Haematol 2010 85 1 5 20192988
14. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM, Cancer 2010 116 3807 3814 10.1002/cncr.25139 20564094
15. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D, Br J Haematol 1998 102 1115 1123 10.1046/j.1365-2141.1998.00930.x 9753033 (Pubitemid 28435189)
16. International uniform response criteria for multiple myeloma. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group, Leukemia 2006 20 1467 1473 10.1038/sj.leu.2404284 16855634 (Pubitemid 44264086)
17. Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JC, Dalton JT, Phelps MA, Ther Drug Monit 2008 30 620 627 10.1097/FTD.0b013e318185813d 18708993
18. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM, Leukemia 2009 23 2147 2152 10.1038/leu.2009.147 19626046
19. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, Facon T, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD, Dimopoulos MA, Eur J Haematol 2009 82 426 432 10.1111/j.1600-0609.2009.01257.x 19302559
20. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL, J Clin Pharmacol 2007 47 1466 1475 10.1177/0091270007309563 17954615 (Pubitemid 350115306)
21. High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. Maisnar V, Hájek R, Scudla V, Gregora E, Büchler T, Tichý M, Kotoucek P, Kafková A, Forraiová L, Minarík J, Radocha J, Bláha V, Malý J, Bone Marrow Transplant 2008 41 51 54 10.1038/sj.bmt.1705881 17934529
22. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Klatsky AL, Armstrong MA, Poggi J, Am J Cardiol 2000 85 1334 1337 10.1016/S0002-9149(00)00766-9 10831950 (Pubitemid 30314667)
23. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. White RH, Zhou H, Romano PS, Ann Intern Med 1998 128 737 740 10.7326/0003-4819-128-9-199805010-00006 9556467 (Pubitemid 28204865)
24. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Chew HK, Wun T, Harvey D, Zhou H, White RH, Arch Intern Med 2006 166 458 464 16505267
25. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators, N Engl J Med 2005 352 2487 2498 10.1056/NEJMoa043445 15958804 (Pubitemid 41007864)
26. Low-dose thalidomide plus dexamethasone is an effective therapy for advanced myeloma. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A, Boccadoro M, Haematologica 2001 86 399 403 11325646 (Pubitemid 32428500)
27. Thalidomide and dexamethasone combination or refractory multiple myeloma. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N, Ann Oncol 2001 12 991 995 10.1023/A: 1011132808904 11521808 (Pubitemid 32725775)
28. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC, Blood 2013 121 1961 1967 10.1182/blood-2012-08-450742 23243282
29. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T, Intergroupe Francophone du Myélome, Blood 2013 121 1968 1975 10.1182/blood-2012-09-452375 23319574
30. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S, Blood 2012 120 2817 2825 10.1182/blood-2012-05-425934 22833546
31. Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment. Yang G, Chen W, Wu Y, Chin J Cancer Res 2013 25 155 160 23592895
32. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, Huang H, Cai Z, Leuk Res 2009 33 1615 1618 10.1016/j.leukres.2009.04.006 19773080